What ANI Pharmaceuticals, Inc. told the SEC could break it.

Consolidation of pharmaceutical distribution has concentrated ANI's revenue in a few drug wholesalers: three customers represented 22%, 17% and 14% of net revenues (≈53% combined) in 2025, with accounts receivable from those three at ~64% of net AR. Loss of, or adverse payment-term renegotiation with, any of these wholesalers would materially affect revenue, liquidity and working capital. The customers are not named in the filing, so this is a quantified customer-concentration risk rather than named edges. (Product concentration compounds it: Cortrophin Gel alone is ~39% of net revenue.)

“our net revenues are concentrated among three customers representing 22%, 17%, and 14% of our net revenues, respectively, during the year ended December 31, 2025.”

ANI generally qualifies only a single source of API for each product because validating a second source is costly and time-consuming, leaving it dependent on current vendors to reliably supply API for ongoing manufacturing; changing an API supplier requires an FDA prior-approval supplement that can take 6–9 months (or longer). Several key products — injectables, softgel capsules, Cortrophin Gel and ILUVIEN — are manufactured and supplied by third parties, in some cases as a single source, and ANI expects reliance on third-party manufacturers to increase. A supply interruption, quality issue, or qualification delay at a sole-source API maker or CMO could halt production of important products. Suppliers unnamed, so a sole-source/supplier-concentration risk.

“Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply.”

Four ANI products — EEMT, Opium Tincture, Thyroid Tablets and Hyoscyamine, together less than 10% of 2025 total revenue — are marketed without approved NDAs or ANDAs under the FDA's risk-based enforcement discretion. ANI cannot be certain the FDA will not change its position and require approval for, or withdrawal of, these products, which would adversely affect results. Several of its products (e.g., Opium Tincture) are also DEA-scheduled controlled substances subject to DEA manufacturing/quota oversight across its U.S. and India operations. A specific, named regulatory/enforcement exposure (bounded by the <10% revenue share).

“Four products, which together comprised less than 10% of our total revenue in 2025, are marketed without approved NDAs or ANDAs and we cannot be certain that the FDA will not require us to either seek approval for these products or withdraw them from the market.”